Associate Professor of Medicine, Harvard Medical School
Director, Dana-Farber Cancer Institute Lynch Syndrome Center
Bio Research Interests Key Publications
Bio
Dr. Yurgelun is a gastrointestinal medical oncologist at the Dana-Farber Cancer Institute who devotes most of his time to the care of patients with GI malignancies as well as patients and families with inherited predisposition to GI cancers. He serves as the Director of the DFCI Lynch Syndrome Center and the Director of Clinical Research for the DFCI Division of Cancer Genetics and Prevention. He sites on numerous national guideline panels related to the evaluation and management of individuals with inherited cancer risk, and he previously served as the elected national President of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer.
Research Interests
Hereditary gastrointestinal cancer syndromes, Lynch syndrome, and pancreatic cancer surveillance
Key Publications
Yurgelun MB*, Chittenden AB*, Morales-Oyarvide V*, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui J, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BM. Germline Cancer Susceptibility Gene Variants, Somatic Second Hits, and Survival Outcomes in Patients with Resected Pancreatic Adenocarcinoma. Genet Med. 2019;21:213-23. PMID: 29961768; PMCID: PMC6666401
Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S. Cancer Susceptibility Gene Mutations in Individuals with Colorectal Cancer. J Clin Oncol. 2017;35:1086-95. PMID: 28135145; PMCID: PMC5455355
Chittenden A, Haraldsdottir S, Ukaegbu C, Underhill-Blazey M, Gaonkar S, Uno H, Brais LK, Perez K, Wolpin BM, Syngal S, Yurgelun MB. Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. JCO Oncol Pract. 2021;17:e236-e247. PMID: 33439686; PMCID: PMC8257923
Yurgelun MB. Germline Testing for Individuals With Pancreatic Cancer: The Benefits and Challenges to Casting a Wider Net. J Clin Oncol. 2017;35:3375-7. PMID: 28834438
Yurgelun MB. Building on More Than 20 Years of Progress in Pancreatic Cancer Surveillance for High-Risk Individuals. J Clin Oncol. 2022;40:3230-4. PMID: 35862875.
